| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.2 |